



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/TG/2025-26/186

March 12, 2026

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
<b>Scrip Code - 532523</b>	<b>Scrip Symbol - Biocon</b>

**Subject: Notification to Stock Exchanges**

Dear Sir/Madam,

This is to inform you that Biocon Pharma Limited, a wholly-owned subsidiary of the Company, has received approval from the U.S Food and Drug Administration (U.S. FDA) for its ANDA for Liraglutide Injection (gVictoza®), 18 mg/3 mL (6 mg/mL), Single-Patient-Use Prefilled Pens. Liraglutide is indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise.

This follows the approval for Liraglutide injection (gSaxenda®) that was received by the Company on February 24, 2026, and will further strengthen Biocon's portfolio of vertically integrated, complex drug products.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

---

**Rajesh Umakant Shanoy**  
**Company Secretary and Compliance Officer**  
**M. No.: ACS 16328**